Welcome to our dedicated page for Siga Technologie news (Ticker: SIGA), a resource for investors and traders seeking the latest updates and insights on Siga Technologie stock.
SIGA Technologies Inc. reports developments as a commercial-stage pharmaceutical company focused on infectious-disease countermeasures, with a primary focus on orthopoxviruses. Its recurring updates center on TPOXX (tecovirimat), including oral and IV product sales, deliveries to large institutional customers and international governments, Strategic National Stockpile activity, and procurement contracts.
Company news also covers quarterly and annual results, research and development revenue, BARDA 19C development funding for pediatric and manufacturing activities, regulatory developments for tecovirimat indications, business update calls, and capital actions such as special cash dividends on common stock.
SIGA Technologies (SIGA) announced approximately $28 million in procurement orders for oral TPOXX (tecovirimat), including $26 million from Canada and $2 million from two new international jurisdictions. The Public Health Agency of Canada (PHAC) ordered $39 million this year, including an increase of $9 million to an existing contract. Overall, SIGA has received $56 million in international orders from six jurisdictions in 2022, highlighting a strong public health reaction to the evolving monkeypox outbreak.
SIGA Technologies, Inc. announced the approval of tecovirimat (oral TPOXX) by the United Kingdom for treating smallpox, monkeypox, cowpox, and vaccinia complications in adults and children over 13kg. This approval enhances health emergency preparedness amid ongoing monkeypox outbreaks. Tecovirimat was previously approved by the FDA in 2018 and by Health Canada in 2021. The company emphasizes the importance of building stockpiles for infectious disease outbreaks and potential bioterror threats.
SIGA Technologies, Inc. (SIGA) announced about $13 million in procurement orders for its antiviral drug, oral TPOXX (tecovirimat). This includes $11 million for initial orders from two new international jurisdictions and $2 million from a country in the Asia Pacific region under an existing contract. The orders are driven by increased inquiries related to the global monkeypox outbreak, with SIGA expected to deliver approximately $4 million within 45 days and the remaining $7 million in 2023. The FDA approved oral TPOXX in 2018 to treat smallpox, highlighting its relevance amidst recent health threats.
SIGA Technologies (SIGA) announced its CEO Phil Gomez and CSO Dennis Hruby will join a panel on June 23, 2022, at 12 PM ET to discuss monkeypox outbreaks in the U.K., EU, and U.S. The event, hosted by Alliance Global Partners, will feature representatives from Emergent Biosolutions and Tonix Pharmaceuticals.
SIGA's lead product, tecovirimat (TPOXX), was approved by the EMA in January 2022 for treating smallpox and monkeypox. Although authorized for smallpox in the U.S., it is not FDA-approved for monkeypox treatment.
SIGA Technologies (SIGA) has received FDA approval for the intravenous (IV) formulation of TPOXX to treat smallpox. This approval allows broader access for patients who cannot take oral medications. The oral formulation is already approved in the US, Canada, and Europe. TPOXX is recognized for its role in U.S. preparedness against biological threats, including smallpox and monkeypox. SIGA remains committed to enhancing public health security through effective countermeasures.
On May 12, 2022, SIGA Technologies, Inc. (SIGA) announced a contract from the U.S. Department of Defense for up to $7.5 million of oral TPOXX, with $3.6 million earmarked for 2022. SIGA is also collaborating with the DoD to develop TPOXX for Post Exposure Prophylaxis (PEP), supported by a $26 million contract. The FDA approved TPOXX in 2018 for smallpox treatment, with further approvals from Health Canada and the European Medicines Agency in 2021 and 2022, respectively. CEO Phil Gomez highlighted the partnership as a significant step in securing customers for TPOXX.
On May 5, 2022, SIGA Technologies reported significant progress with the first sale of intravenous TPOXX to the U.S. government under the 19C BARDA contract, generating $7 million in revenue. The company also secured a new contract in Asia Pacific for $3 million of oral TPOXX. Financially, total revenues reached $10.5 million in Q1 2022, compared to $4.8 million in Q1 2021. A special dividend of $0.45 per share has been declared, payable on June 2, 2022. Additionally, the company repurchased 1 million shares for $6.6 million, reflecting confidence in continued growth.
SIGA Technologies, Inc. (SIGA) has declared a special dividend of $0.45 per share on its common stock. This dividend will be payable on June 2, 2022, to shareholders recorded by the end of business on May 17, 2022. CEO Phil Gomez stated that this decision reflects the company's strong financial performance in 2020 and 2021, along with confidence in future prospects. SIGA specializes in countermeasures for health security, notably its lead product TPOXX, an antiviral for smallpox, with significant orders from the U.S. government amounting to approximately $705 million.
SIGA Technologies, Inc. (SIGA) announced a business update webcast scheduled for May 5, 2022, at 4:30 P.M. ET. The call will feature key executives including CEO Dr. Phil Gomez and CFO Daniel Luckshire. SIGA focuses on health security, with its primary product being TPOXX, an antiviral drug for smallpox, backed by approximately $705 million in U.S. government procurement. The oral formulation of TPOXX received FDA approval in 2018, while the EMA approved it in January 2022. More details are available on SIGA's website.
SIGA Technologies, Inc. (SIGA) reported robust financial results for 2021, achieving $133.7 million in total revenues, an increase from $89.1 million in 2020. The company delivered approximately $113 million of its oral TPOXX® to the U.S. government, amid significant supply chain challenges. International product sales rose to $13 million, compared to $2 million in 2020. SIGA also repurchased 3.8 million shares, representing about 5% of shares outstanding. With EMA approval for oral Tecovirimat in early 2022, SIGA is well-positioned for further growth.